Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939599 · ClinicalTrials.gov registry record · Phase 2
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02939599 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT02939599, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving QCC374. The study will monitor the long-term safety, tolerability and efficacy of QCC374 in patients with PAH.
Interventions
- DRUG QCC374
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2018-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02939599
The ClinicalTrials.gov registry entry for NCT02939599 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QCC374 is the first listed.
NCT02939599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02939599 about?
NCT02939599 is a clinical study titled "Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients". This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving QCC374. The study will monitor the long-term safety, tolerability and efficac...
What is the current status of trial NCT02939599?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-02-01. Estimated completion is 2018-11-06.
What interventions are being tested in trial NCT02939599?
The interventions under investigation include: QCC374 (DRUG).
Who is sponsoring clinical trial NCT02939599?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.